Approval · Notice of Compliance 21311 · 2018
DUAVIVE: Notice of Compliance 21311
Issued September 14, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21311
- Date
- September 14, 2018
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DUAVIVE | Not yet assigned | — |
Medicinal ingredients
- CONJUGATED ESTROGENS 0.45 MG per TAB
- BAZEDOXIFENE ACETATE 20 MG per TAB